Cademy logoCademy Marketplace
  • Professional Development
  • Medicine & Nursing
  • Arts & Crafts
  • Health & Wellbeing
  • Personal Development

215 Educators providing Courses

disease
Third Level Foundation

third level foundation

Aberdeen

Within the World Health Organisation (WHO) - "Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.", while Mental Health is defined as "a state of well-being in which every individual realises his or her own potential, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to her or his community." We believe that improving Mental Health improves General Health and Well-being. The two types of health are linked yet we tend to treat them with different priorities. When someone breaks an arm, they go to see a doctor. When that same person has a problem with their mental health, they may be more hesitant about looking for support. When their problem gets worse it can create stress in those around them. Although we are living in the 21st Century, Mental Health is often perceived as less important than physical health, and is not treated as a priority.

Message
Respiratory Matters

respiratory matters

Meltham

Respiratory Matters was founded in 2011, and has provided training and education to hundreds of health care professionals throughout the UK. In 2016 we were awarded the Quality Assurance Certificate from Health Education Yorkshire and the Humber. Our mission is to improve the care and outcomes of people with respiratory disease through evidence-based, practical, high quality education. Our courses are accredited by the CPD certification service. Accredited CPD training means the learning activity has reached the required Continuing Professional Development standards and benchmarks. The learning value has been scrutinised to ensure integrity and quality. The CPD Certification Service provides recognised independent CPD accreditation compatible with global CPD requirements We deliver asthma and COPD Certificate and Diploma courses,and spirometry Foundation, Interpretation and Full Certificate courses. As well as delivering our accredited courses throughout the UK, we are regularly commissioned by CCG's and PCN's to provide education in their localities. In addition to education, we frequently work with CCG’s leading on their local respiratory projects. We are also involved in respiratory research and digital innovation.

Message
Community Chef - Good Food for All

community chef - good food for all

4.7(16)

Since 2001, Community Chef has helped thousands of people to improve their cookery and nutrition skills. We use food and cookery as tools for developing communities while promoting health and wellness.

Message
Bristol Myers Squibb

bristol myers squibb

Uxbridge

Bristol Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients—it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, haematology, cardiology, immunology, fibrosis, and specialty medicines. Through our Research & Development organisation, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work. As global citizens, we work sustainably and responsibly and seek to give back. Through the Bristol Myers Squibb Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.

Message
Pcsk9 Education And Research Forum

pcsk9 education and research forum

Alcester

Reducing low density lipoprotein (LDL) cholesterol is the priority in managing patients with severe dyslipidaemia (cholesterol abnormality) and at high risk of cardiovascular (CV) death and disability. Yet even when treated with potent statins, many patients fail to achieve LDL-cholesterol targets and therefore their risk of accelerated atherosclerosis and CV death remains high. This problem is particularly critical in patients with familial hypercholesterolaemia (FH) (the most commonly occurring genetic condition in the world). People with FH typically have very high LDL cholesterol levels on treatment, and consequently, are at very high risk of premature and sudden CV death, myocardial infarction and stroke. Additionally, some patients are unable to tolerate statins – particularly at higher doses – and, therefore, do not achieve LDL-cholesterol goals. What is the importance of PCSK9? Discovered in 2003,1 PCSK9 is a protein made by the liver which increases the removal of LDL receptors from the surface of liver cells. These LDL receptors are critically important in removal of serum LDL-cholesterol from the circulation. People with so-called ‘gain of function’ PCSK9 mutations over-express PCSK9, and therefore have very high plasma levels of LDL cholesterol and are at very risk of atherosclerosis and CV mortality and morbidity.2 In contrast, people with so-called ‘loss of function’ PCSK9 mutations, have very LDL cholesterol levels and reduced risk for heart disease.3 What is PCSK9 inhibition? Different approaches to lowering PCSK9 are now licensed. These include fully human monoclonal antibodies (alirocumab, evolocumab) and a small-interfering RNA therapy (inclisiran). Trials show that these PCSK9 inhibitors reduce LDL cholesterol levels by about 50-60 percent - a significantly greater effect than that achieved with currently available therapies – either when given alone or in combination. These LDL cholesterol lowering effects have been consistently across a broad group of patients, including those with familial hypercholesterolaemia in clinical trials.4 Which clinical settings will benefit from the availability of PCSK9 inhibitors? These treatments offer the potential to reduce cardiovascular risk in patients whose clinical needs cannot be satisfied by current therapy. These include: Patients with familial hypercholesterolaemia – an inherited disorder of lipid metabolism with a very high risk of early CV death or morbidity, if not diagnosed or treated early Patients who cannot tolerate statins, who therefore remain at high risk of CV events such as heart attacks and strokes Patients with established heart disease who have not achieved LDL-cholesterol goals despite current therapies

Message
London School of Hygiene and Tropical Medicine

london school of hygiene and tropical medicine

London

The London School of Hygiene & Tropical Medicine is renowned for its research, postgraduate studies and continuing education in public and global health. We have an annual research income of more than £180 million and are one of the highest-rated research institutions in the UK.

Message
Pochat Training

pochat training

5.0(50)

Chesterfield

We run fun and engaging, interactive and varied training courses in a wide variety of subjects, that are Ofqual regulated and/or CPD Accredited:   🔸 Mental Health First Aid 🔸Wellbeing 🔸 First Aid 🔸 Food Safety 🔸 Fire Safety 🔸 citizenAID 🔸 Health and Safety 🔸 Manual Handling 🔸 Health and Social Care 🔸 Education and Training 🔸 Educational Courses 🔸 Digital (Computer) and Functional Skills We care about teaching, about making it fun and engaging, about ensuring that learners can apply what they have learned into their workplaces and daily lives. We care.   Join us either in open (public) or in-house (private) courses, or ask us about bespoke courses created specifically to suit your specific needs. For all of our courses, including our wide range of Ofqual regulated ones, do have a look at our Courses leaflet, or contact us to discuss your training needs. The dates below are now past, but we're still running all of these CPD Accredited courses - and a lot of Ofqual Regulated ones besides!

Message
Doctors With M.e. Community Interest Company

doctors with m.e. community interest company

London

To improve patient outcomes worldwide by empowering medics, scientists and policymakers with up-to-date practices and scientific rigour, fostering collaboration between professionals, the industries they serve, patients and the public. To build a future where every surgery, hospital, agency, insurance provider and employer is enabled with accurate information that supports their patients, clients, shareholders and wider stakeholders. Who and where we are Doctors with M.E. is the global professional association for medical practitioners and scientists in the field, bringing together leading experts, regional associations and the quarter of a million healthcare professionals with ME that already existed pre-pandemic. We are a unique authority on myalgic encephalomyelitis and those Long Covid patients acknowledged by NIH, NIAID and BMA narratives who risk progression to this neuroimmune disease. With professional backgrounds developed in hospitals, surgeries, universities, financial services and think-tanks, our range of expertise is both specific and multidisciplinary. The first global professional association in the field, we are also the first to be established and led by medics and experts who suffer from ME themselves. We are Doctors with ME and Doctors who stand with ME.

Message
IFM Group Education

ifm group education

Information and educational seminars and conferences on functional medicine.The Institute for Functional Medicine (IFM) affirms its commitment for a more diverse, equitable, and inclusive (DEI) future for the functional medicine and wellness field. Through creating a culture of belonging (B) for its team members, IFM will partner with others in our collective responsibility to help advance health equity for all patients, practitioners, and individuals worldwide. At IFM, each human being is an important and valued member of our team. IFM is dedicated to nourishing an inclusive culture of respect and belonging–acknowledging and celebrating each team member’s unique identities, expressions, backgrounds, perspectives, and expertise. Through embracing our differences and fostering equity, IFM may serve the growing and diverse community of practitioners and patients. As the nonprofit leader in the field of functional medicine, IFM has the ability and more importantly the responsibility to help patients rise from the ravages of chronic and infectious disease and to help optimize their innate capacities for healing, balance, and well-being. This critically important work is only possible through linking arms with others, embracing our common goals, and stepping forward together to ensure the greatest expression of health and well-being for all.

Message
Galapagos Biotech

galapagos biotech

We are a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union, Norway, Great Britain, and Japan. Our mission is to develop transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Through the combined acquisition of CellPoint and AboundBio, we are adding a new therapy and disease area to its current small molecules portfolio: cell therapy, a potential transformative treatment of different types of cancer. It propels us into next-generation cell therapies, while significantly broadening our portfolio and capabilities. We employ more than 1,300 employees worldwide, with sites in Belgium (international headquarters), the Netherlands, France, Germany, Austria, Italy, Spain, the Nordics, Switzerland, the UK and the US.

Message
1...1112131415...22

Search By Location